Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens has been weighing whether to take the company private in what would be the largest leveraged buyout in history, people familiar with the situation told CNBC.

Walgreens shares jump on report of formal offer to go private from KKR

Walgreens is taking steps to distance the pharmacy chain from drug wholesalers like AmerisourceBergen as opioid litigation intensifies.

Amid Opioid Lawsuits, Walgreens Wants Distance From AmerisourceBergen

Walgreens: Update On Restructuring

Deutsche Bank

FedEx

Mylan

Occidental Petroleum

POSCO

Schlumberger

These large-cap stocks are names to avoid, particularly in a time of global recession and geopolitical tension. Bigger isn't always better.

7 Large-Cap Stocks to Give a Wide Berth

Biogen

New data on Biogen's formerly shelved Alzheimer's disease drug puts it on a path toward blockbuster status, but it will have to win regulatory approval first.

Biogen's Alzheimer's Drug Goes From Bust to Boon, Plus Why Walgreens Is Shuttering 200 Healthcare Clinics

Settlements by Walgreens Boots Alliance of opioid litigation could play into any decision of private equity firms to finance a leveraged buyout of the drugstore chain.

Opioid Litigation Looms Over Walgreens LBO

Walgreens stock has rallied to a seven-month high after reports that the drug chain is talking to private equity firms about a leveraged buyout.

Walgreens Stock Flying High After Buyout Reports

Dow Inc

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The "Mad Money" host says Walgreens Boots Alliance, Dow Inc. and Verizon are worth keeping an eye on, based on Dan Fitzpatrick's technical analysis.

Jim Cramer: These are the 3 high-yield stocks that could drive the Dow higher

The company is reportedly in talks with private equity buyers.

Why Shares of Walgreens Spiked Today

It’s one thing to think that there is a value investor’s dream awaiting in the shares of Walgreens Boots Alliance Inc.

Many Problems & Caveats Face Any Would-Be Acquirer of Walgreens, Even Warren Buffett

Drug store giant Walgreens Boots Alliance is one of the worst stocks in the Dow this year. But shares shot up Tuesday after Reuters reported that the company is considering taking itself private.

It's one of the Dow's worst performers this year, but shares climbed on a report it may go private

Dow Jones stock Walgreens Boots Alliance rose on news it had held talks to go private in what would be the biggest leveraged buyout in history.

The Newest Dow Jones Stock May Be About To Leave Already

Walgreens Boots Alliance has been in discussions with major private equity firms to possibly take the global drugstore chain private, according to media reports.

Report: Walgreens Considering Leveraged Buyout

Drug store chain Walgreens Boots Alliance (NASDAQ: WBA) has been in discussion on whether to go private following private equity interest, according to a Reuters report.

Report: Walgreens Explores Going Private

Shares of Walgreens Boots Alliance Inc. WBA, +4.03% shot up 4.2% in afternoon trading, after soaring 8.9% over the previous two sessions, after a Reuters report that the drug store chain has been exploring a deal to go private.

Walgreens' stock surges again, after report company was exploring a deal to go private

Walgreens Boots Alliance Inc  has been exploring whether to go private following private equity interest in the U.S drug store chain, according to people familiar with the matter.

Exclusive: Walgreens has explored taking drug store chain private - sources

Shares of Walgreens Boots Alliance rose more than 7% on reports the company has been exploring a deal to go private.

Walgreens shares rise on report company is in talks to go private

Chico's FAS

Kirkland's

Macy's

Signet Jewelers

SmartRent

Tile Shop Hlds

A strong U.S. consumer can't save all retail stocks.

7 Retail Stocks to Avoid for the Holidays

Boeing

Caterpillar

Cisco Systems

Chevron

Goldman Sachs

Intel

Johnson & Johnson

McDonald's

Merck

Travelers

UnitedHealth Group

Exxon Mobil

When investors hear that the stock market just hit a new all-time high, it’s probably fairly easy to assume that this means almost all the individual stocks are probably at all-time highs as well.

As the Dow Hits All-Time High, Over Half of Dow Stocks Keep Disappointing Investors

The drugstore chain is leaving no stone unturned, and the initiatives are being handled so as to minimize potential downsides.

Partnerships Give Walgreens Much-Needed Growth Potential, but Investors Need to Be Patient

Walgreens' CEO, billionaire Staffano Pessina, is purely a retailer and running the company like one, while rival CVS Health becomes a managed care company.
The post Earnings Show Walgreens Stock Is Still Going in the Wrong Direction appeared first on InvestorPlace.

Earnings Show Walgreens Stock Is Still Going in the Wrong Direction

AGNC Investment

British American Tobacco

Cardinal Health

Equinor

Energy Transfer LP Unit

Iron Mountain

Leggett & Platt

Altria

MPLX

Bank OZK

Packaging Corp of America

Philip Morris

Taubman Centers

I've put good amounts of capital to work, investing heavily into tobacco, oil/energy and some miscellaneous companies as well.

October Portfolio Update - Extensive Buys, More Oil And FX

The drugstore chain just said something that should concern rival players looking to diversify their services.

Walgreens' Exit From Health Clinic Business Is a Warning to Rivals

Comparable sales rose in U.S. Walgreens pharmacies, while de-emphasis of tobacco and suspending e-cigarettes hit the bottom line.

Walgreens Beats Earnings but Remains in Trading Range

This old business may have what it takes to keep up with fast-moving market demands.

News for Walgreens Stock (WBA)